NCT01406314View on ClinicalTrials.gov

SAP Depleter Dose Assessment Study in Patients

PHASE1CompletedINTERVENTIONAL

Enrollment

17

Participants

Timeline

Start Date

October 13, 2011

Primary Completion Date

November 14, 2012

Study Completion Date

November 14, 2012

Conditions

Amyloidosis

Interventions

DRUG

GSK2315698

Intravenous infusion for approximately 48hours followed by subcutaneous injection

Trial Locations (1)

CB2 2GG

GSK Investigational Site, Cambridge

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT01406314 - SAP Depleter Dose Assessment Study in Patients | Biotech Hunter | Biotech Hunter